1
|
Mendez-David I, Schofield R, Tritschler L, Colle R, Guilloux JP, Gardier AM, Corruble E, Hen R, David DJ. Reviving through human hippocampal newborn neurons. Encephale 2021; 48:179-187. [PMID: 34649711 DOI: 10.1016/j.encep.2021.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Revised: 09/02/2021] [Accepted: 09/13/2021] [Indexed: 11/17/2022]
Abstract
Recent contradictory data has renewed discussion regarding the existence of adult hippocampal neurogenesis (AHN) in humans, i.e., the continued production of new neurons in the brain after birth. The present review revisits the debate of AHN in humans from a historical point of view in the face of contradictory evidence, analyzing the methods employed to investigate this phenomenon. Thus, to date, of the 57 studies performed in humans that we reviewed, 84% (48) concluded in favor of the presence of newborn neurons in the human adult hippocampus. Besides quality of the tissue (such as postmortem intervals below 26hours as well as tissue conservation and fixation), considerations for assessing and quantify AHN in the human brain require the use of stereology and toxicological analyses of clinical data of the patient.
Collapse
Affiliation(s)
- I Mendez-David
- CESP, MOODS Team, Inserm, faculté de pharmacie, université Paris-Saclay, 92296 Châtenay-Malabry, France
| | - R Schofield
- CESP, MOODS Team, Inserm, faculté de pharmacie, université Paris-Saclay, 92296 Châtenay-Malabry, France
| | - L Tritschler
- CESP, MOODS Team, Inserm, faculté de pharmacie, université Paris-Saclay, 92296 Châtenay-Malabry, France
| | - R Colle
- CESP, MOODS Team, Inserm, faculté de médecine, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France; Service hospitalo-universitaire de psychiatrie de Bicêtre, hôpital de Bicêtre, hôpitaux universitaires Paris-Saclay, Assistance publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre, France
| | - J-P Guilloux
- CESP, MOODS Team, Inserm, faculté de pharmacie, université Paris-Saclay, 92296 Châtenay-Malabry, France
| | - A M Gardier
- CESP, MOODS Team, Inserm, faculté de pharmacie, université Paris-Saclay, 92296 Châtenay-Malabry, France
| | - E Corruble
- CESP, MOODS Team, Inserm, faculté de médecine, université Paris-Saclay, 94275 Le Kremlin-Bicêtre, France; Service hospitalo-universitaire de psychiatrie de Bicêtre, hôpital de Bicêtre, hôpitaux universitaires Paris-Saclay, Assistance publique-Hôpitaux de Paris, 94275 Le Kremlin-Bicêtre, France
| | - R Hen
- Department of Psychiatry, Columbia University, New York, NY 10032, USA; Division of Systems Neuroscience, Research Foundation for Mental Hygiene, Inc (RFMH)/New York State Psychiatric Institute (NYSPI), New York, NY 10032, USA; Department of Neuroscience, Columbia University, New York, NY 10032, USA
| | - D J David
- CESP, MOODS Team, Inserm, faculté de pharmacie, université Paris-Saclay, 92296 Châtenay-Malabry, France.
| |
Collapse
|
2
|
Lugert S, Kremer T, Jagasia R, Herrmann A, Aigner S, Giachino C, Mendez-David I, Gardier AM, Carralot JP, Meistermann H, Augustin A, Saxe MD, Lamerz J, Duran-Pacheco G, Ducret A, Taylor V, David DJ, Czech C. Glypican-2 levels in cerebrospinal fluid predict the status of adult hippocampal neurogenesis. Sci Rep 2017; 7:46543. [PMID: 28440309 PMCID: PMC5404329 DOI: 10.1038/srep46543] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2016] [Accepted: 03/17/2017] [Indexed: 12/20/2022] Open
Abstract
Adult hippocampal neurogenesis is a remarkable form of brain plasticity through which new neurons are generated throughout life. Despite its important roles in cognition and emotion and its modulation in various preclinical disease models, the functional importance of adult hippocampal neurogenesis in human health has not been revealed because of a lack of tools for monitoring adult neurogenesis in vivo. Therefore, we performed an unbiased proteomics screen to identify novel proteins expressed during neuronal differentiation using a human neural stem cell model, and we identified the proteoglycan Glypican-2 (Gpc2) as a putative secreted marker of immature neurons. Exogenous Gpc2 binds to FGF2 and inhibits FGF2-induced neural progenitor cell proliferation. Gpc2 is enriched in neurogenic regions of the adult brain. Its expression is increased by physiological stimuli that increase hippocampal neurogenesis and decreased in transgenic models in which neurogenesis is selectively ablated. Changes in neurogenesis also result in changes in Gpc2 protein level in cerebrospinal fluid (CSF). Gpc2 is detectable in adult human CSF, and first pilot experiments with a longitudinal cohort indicate a decrease over time. Thus, Gpc2 may serve as a potential marker to monitor adult neurogenesis in both animal and human physiology and disease, warranting future studies.
Collapse
Affiliation(s)
- S Lugert
- Roche Pharmaceutical Research and Early Development, NORD Discovery &Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - T Kremer
- Roche Pharmaceutical Research and Early Development, NORD Discovery &Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - R Jagasia
- Roche Pharmaceutical Research and Early Development, NORD Discovery &Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - A Herrmann
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - S Aigner
- Roche Pharmaceutical Research and Early Development, NORD Discovery &Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - C Giachino
- Embryology and Stem Cell Biology, Department of Biomedicine, University of Basel, Mattenstrasse 28, CH-4058 Basel, Switzerland
| | - I Mendez-David
- CESP/UMR-S 1178, Univ. Paris-Sud, Fac. Pharmacie, INSERM, Université Paris-Saclay, Chatenay Malabry, 92290, France
| | - A M Gardier
- CESP/UMR-S 1178, Univ. Paris-Sud, Fac. Pharmacie, INSERM, Université Paris-Saclay, Chatenay Malabry, 92290, France
| | - J P Carralot
- Roche Pharmaceutical Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - H Meistermann
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - A Augustin
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - M D Saxe
- Roche Pharmaceutical Research and Early Development, NORD Discovery &Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - J Lamerz
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - G Duran-Pacheco
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - A Ducret
- Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| | - V Taylor
- Embryology and Stem Cell Biology, Department of Biomedicine, University of Basel, Mattenstrasse 28, CH-4058 Basel, Switzerland
| | - D J David
- CESP/UMR-S 1178, Univ. Paris-Sud, Fac. Pharmacie, INSERM, Université Paris-Saclay, Chatenay Malabry, 92290, France
| | - C Czech
- Roche Pharmaceutical Research and Early Development, NORD Discovery &Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
| |
Collapse
|
3
|
Pham TH, Mendez-David I, Defaix C, Guiard BP, Tritschler L, David DJ, Gardier AM. Ketamine treatment involves medial prefrontal cortex serotonin to induce a rapid antidepressant-like activity in BALB/cJ mice. Neuropharmacology 2016; 112:198-209. [PMID: 27211253 DOI: 10.1016/j.neuropharm.2016.05.010] [Citation(s) in RCA: 82] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 05/09/2016] [Accepted: 05/15/2016] [Indexed: 11/18/2022]
Abstract
Unlike classic serotonergic antidepressant drugs, ketamine, an NMDA receptor antagonist, exhibits a rapid and persistent antidepressant (AD) activity, at sub-anaesthetic doses in treatment-resistant depressed patients and in preclinical studies in rodents. The mechanisms mediating this activity are unclear. Here, we assessed the role of the brain serotonergic system in the AD-like activity of an acute sub-anaesthetic ketamine dose. We compared ketamine and fluoxetine responses in several behavioral tests currently used to predict anxiolytic/antidepressant-like potential in rodents. We also measured their effects on extracellular serotonin levels [5-HT]ext in the medial prefrontal cortex (mPFCx) and brainstem dorsal raphe nucleus (DRN), a serotonergic nucleus involved in emotional behavior, and on 5-HT cell firing in the DRN in highly anxious BALB/cJ mice. Ketamine (10 mg/kg i.p.) had no anxiolytic-like effect, but displayed a long lasting AD-like activity, i.e., 24 h post-administration, compared to fluoxetine (18 mg/kg i.p.). Ketamine (144%) and fluoxetine (171%) increased mPFCx [5-HT]ext compared to vehicle. Ketamine-induced AD-like effect was abolished by a tryptophan hydroxylase inhibitor, para-chlorophenylalanine (PCPA) pointing out the role of the 5-HT system in its behavioral activity. Interestingly, increase in cortical [5-HT]ext following intra-mPFCx ketamine bilateral injection (0.25 μg/side) was correlated with its AD-like activity as measured on swimming duration in the FST in the same mice. Furthermore, pre-treatment with a selective AMPA receptor antagonist (intra-DRN NBQX) blunted the effects of intra-mPFCx ketamine on both the swimming duration in the FST and mPFCx [5-HT]ext suggesting that the AD-like activity of ketamine required activation of DRN AMPA receptors and recruited the prefrontal cortex/brainstem DRN neural circuit in BALB/c mice. These results confirm a key role of cortical 5-HT release in ketamine's AD-like activity following the blockade of glutamatergic NMDA receptors. Tight interactions between mPFCx glutamatergic and serotonergic systems may explain the differences in this activity between ketamine and fluoxetine in vivo. This article is part of the Special Issue entitled 'Ionotropic glutamate receptors'.
Collapse
Affiliation(s)
- T H Pham
- Université Paris-Saclay, Univ. Paris-Sud, Faculté de Pharmacie, INSERM UMR-S 1178, Chatenay Malabry, 92290, France
| | - I Mendez-David
- Université Paris-Saclay, Univ. Paris-Sud, Faculté de Pharmacie, INSERM UMR-S 1178, Chatenay Malabry, 92290, France
| | - C Defaix
- Université Paris-Saclay, Univ. Paris-Sud, Faculté de Pharmacie, INSERM UMR-S 1178, Chatenay Malabry, 92290, France
| | - B P Guiard
- UMR5169 CNRS "Centre de Recherches sur la Cognition Animale », Toulouse, 31062, France
| | - L Tritschler
- Université Paris-Saclay, Univ. Paris-Sud, Faculté de Pharmacie, INSERM UMR-S 1178, Chatenay Malabry, 92290, France
| | - D J David
- Université Paris-Saclay, Univ. Paris-Sud, Faculté de Pharmacie, INSERM UMR-S 1178, Chatenay Malabry, 92290, France
| | - A M Gardier
- Université Paris-Saclay, Univ. Paris-Sud, Faculté de Pharmacie, INSERM UMR-S 1178, Chatenay Malabry, 92290, France.
| |
Collapse
|
4
|
Mendez-David I, Hen R, Gardier AM, David DJ. Adult hippocampal neurogenesis: an actor in the antidepressant-like action. Ann Pharm Fr 2013; 71:143-9. [PMID: 23622692 DOI: 10.1016/j.pharma.2013.02.006] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2013] [Revised: 02/23/2013] [Accepted: 02/28/2013] [Indexed: 01/20/2023]
Abstract
Depression and anxiety are psychiatric illnesses that are major burdens in society and affect as much as 7% of the world's population. The heterogeneous nature of depression suggests an involvement of multiple distinct brain regions including amygdala, prefrontal cortex and the hippocampus, which may be responsible for the diversity of the symptoms. Besides its critical role in learning and memory, the hippocampus is one of only two areas in mammalian brain where adult neurogenesis occurs. Of the current leading hypotheses of the pathophysiology and treatment of depression, the neurogenesis hypothesis of depression deserves particular attention because changes in neurogenesis are only seen after chronic, but not acute, antidepressant treatment. This review revisits the role of adult hippocampal neurogenesis in the pathophysiology of mood disorders, especially anxiety/depression, and also in the antidepressant-like responses, especially in stressed rodents.
Collapse
Affiliation(s)
- I Mendez-David
- EA 3544 pharmacologie des troubles anxio-dépressifs et neurogenèse, faculté de pharmacie, université Paris-Sud, Tour D1, 2(e) étage, 5, rue J.-B.-Clement, 92296 Chatenay-Malabry cedex, France
| | | | | | | |
Collapse
|